Stock Analysis on Net
Stock Analysis on Net

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)

DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin

Microsoft Excel

Decomposing ROE involves expressing net income divided by shareholders’ equity as the product of component ratios.

Two-Component Disaggregation of ROE

Regeneron Pharmaceuticals Inc., decomposition of ROE

Microsoft Excel
ROE = ROA × Financial Leverage
Dec 31, 2023 15.22% = 11.95% × 1.27
Dec 31, 2022 19.14% = 14.85% × 1.29
Dec 31, 2021 43.03% = 31.75% × 1.36
Dec 31, 2020 31.86% = 20.47% × 1.56
Dec 31, 2019 19.08% = 14.29% × 1.34

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

The primary reason for the decrease in return on equity ratio (ROE) over 2023 year is the decrease in profitability measured by return on assets ratio (ROA).

Three-Component Disaggregation of ROE

Regeneron Pharmaceuticals Inc., decomposition of ROE

Microsoft Excel
ROE = Net Profit Margin × Asset Turnover × Financial Leverage
Dec 31, 2023 15.22% = 30.14% × 0.40 × 1.27
Dec 31, 2022 19.14% = 35.64% × 0.42 × 1.29
Dec 31, 2021 43.03% = 50.25% × 0.63 × 1.36
Dec 31, 2020 31.86% = 41.35% × 0.50 × 1.56
Dec 31, 2019 19.08% = 26.91% × 0.53 × 1.34

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

The primary reason for the decrease in return on equity ratio (ROE) over 2023 year is the decrease in profitability measured by net profit margin ratio.

Five-Component Disaggregation of ROE

Regeneron Pharmaceuticals Inc., decomposition of ROE

Microsoft Excel
ROE = Tax Burden × Interest Burden × EBIT Margin × Asset Turnover × Financial Leverage
Dec 31, 2023 15.22% = 0.94 × 0.98 × 32.57% × 0.40 × 1.27
Dec 31, 2022 19.14% = 0.89 × 0.99 × 40.40% × 0.42 × 1.29
Dec 31, 2021 43.03% = 0.87 × 0.99 × 58.38% × 0.63 × 1.36
Dec 31, 2020 31.86% = 0.92 × 0.99 × 45.51% × 0.50 × 1.56
Dec 31, 2019 19.08% = 0.87 × 0.99 × 31.28% × 0.53 × 1.34

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

The primary reason for the decrease in return on equity ratio (ROE) over 2023 year is the decrease in operating profitability measured by EBIT margin ratio.

Two-Component Disaggregation of ROA

Regeneron Pharmaceuticals Inc., decomposition of ROA

Microsoft Excel
ROA = Net Profit Margin × Asset Turnover
Dec 31, 2023 11.95% = 30.14% × 0.40
Dec 31, 2022 14.85% = 35.64% × 0.42
Dec 31, 2021 31.75% = 50.25% × 0.63
Dec 31, 2020 20.47% = 41.35% × 0.50
Dec 31, 2019 14.29% = 26.91% × 0.53

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

The primary reason for the decrease in return on assets ratio (ROA) over 2023 year is the decrease in profitability measured by net profit margin ratio.

Four-Component Disaggregation of ROA

Regeneron Pharmaceuticals Inc., decomposition of ROA

Microsoft Excel
ROA = Tax Burden × Interest Burden × EBIT Margin × Asset Turnover
Dec 31, 2023 11.95% = 0.94 × 0.98 × 32.57% × 0.40
Dec 31, 2022 14.85% = 0.89 × 0.99 × 40.40% × 0.42
Dec 31, 2021 31.75% = 0.87 × 0.99 × 58.38% × 0.63
Dec 31, 2020 20.47% = 0.92 × 0.99 × 45.51% × 0.50
Dec 31, 2019 14.29% = 0.87 × 0.99 × 31.28% × 0.53

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

The primary reason for the decrease in return on assets ratio (ROA) over 2023 year is the decrease in operating profitability measured by EBIT margin ratio.

Disaggregation of Net Profit Margin

Regeneron Pharmaceuticals Inc., decomposition of net profit margin ratio

Microsoft Excel
Net Profit Margin = Tax Burden × Interest Burden × EBIT Margin
Dec 31, 2023 30.14% = 0.94 × 0.98 × 32.57%
Dec 31, 2022 35.64% = 0.89 × 0.99 × 40.40%
Dec 31, 2021 50.25% = 0.87 × 0.99 × 58.38%
Dec 31, 2020 41.35% = 0.92 × 0.99 × 45.51%
Dec 31, 2019 26.91% = 0.87 × 0.99 × 31.28%

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

The primary reason for the decrease in net profit margin ratio over 2023 year is the decrease in operating profitability measured by EBIT margin ratio.